✦ LIBER ✦

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

✍ Scribed by Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa

Book ID: 117785856
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 217 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(11)70336-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P301 Addition of pertuzumab (P) to trast

P301 Addition of pertuzumab (P) to trastuzumab (H)-based neoadjuvant chemotherapy significantly improves pathological complete response in women with HER2-positive early breast cancer: Result of a randomised phase II study (NEOSPHERE)

✍ L. Gianni; T. Pienkowski; Y.-H. Im; L. Roman; L.-M. Tseng; M.-C. Liu; A. Lluch-H 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 37 KB

Lapatinib with trastuzumab for HER2-posi

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

✍ De Azambuja, Evandro (author);Holmes, Andrew P. (author);Piccart-Gebhart, Martin 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 325 KB

Lapatinib with trastuzumab for HER2-posi

✍ De Azambuja, Evandro (author);Holmes, Andrew P. (author);Piccart-Gebhart, Martin 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 325 KB

Neoadjuvant and adjuvant trastuzumab in

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

✍ Gianni, Luca; Eiermann, Wolfgang; Semiglazov, Vladimir; Lluch, Ana; Tjulandin, S 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 294 KB

Safety and efficacy of the combination o

Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK

✍ K.T. Papazisis; T. Habeshaw; D.W. Miles 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB

PO59 EFFICACY AND SAFETY OF EVEROLIMUS P

PO59 EFFICACY AND SAFETY OF EVEROLIMUS PLUS EXEMESTANE COMBINATION THERAPY VERSUS MONOTHERAPY WITH EVEROLIMUS OR CAPECITABINE IN HR+, HER2− BREAST CANCER: A MULTI-CENTER, OPEN-LABEL, PHASE 2 TRIAL BOLERO-6

✍ de Boer, Richard; Jerusalem, Guy; Hurvitz, Sara; Ejlertsen, Bent; El-Hashimy, Mo 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 53 KB